A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
Conditions
- Solid Tumor Malignancies, Cancer
- Solid Cancers
- Solid Tumor Cancer
- Solid Tumor, Unspecified, Adult
- Solid Tumour
- Solid Tumors Refractory to Standard Therapy
- HCC - Hepatocellular Carcinoma
- RCC, Renal Cell Cancer
- Pancreas Cancer
Interventions
- DRUG: LXP1788 is administered intravenously via Port-A
Sponsor
LaunXP Biomedical Co., Ltd.
Collaborators